Lenvatinib treatment strategy for thyroid carcinoma with malignant pleurisy: a case report.

ABSTRACT:

Background

Although lenvatinib is effective for unresectable thyroid carcinoma, it may cause adverse events owing to rapid tumor shrinkage or necrosis. Pneumothorax during lenvatinib therapy is rare. However, once it occurs, it can become a refractory and fatal complication. Herein, we report two cases of thyroid carcinoma with malignant pleurisy treated with lenvatinib and discuss treatment strategies to prevent pneumothorax.

Case description

The first case involved a 78-year-old male with papillary thyroid carcinoma and malignant bilateral pleural effusion. He underwent pleurodesis with talc for the left pleural effusion due to respiratory distress, and lenvatinib therapy was initiated. Forty days after lenvatinib therapy, the patient developed a right pneumothorax and und

SUBMITTER: Sakamoto S 

PROVIDER: S-EPMC11558289 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature